A Pharmacokinetics Study of MultiHance in Pediatric Patients

A Clinical Investigation of the Pharmacokinetics and Safety of MultiHance in Patients From 2-5 Years of Age Undergoing A Clinical Indicated MRI of the CNS

Compare relative exposure in the younger age group in order to supplement the PK profile already determined in older children and adults

Inclusion Criteria:

• Male or female between 2 and 5 years of age
• Obtained informed consent from patient's parent or guardian
• Obtain assent when applicable according to local law
• Known or suspected disease of the central nervous system (brain or spine)
• Referred for MRI of the brain or spine requiring an injection of an MR contrast agent

Exclusion Criteria:

• Contraindications to MR examination
• Undergoing MRI in an emergency situation
• Known allergy to one or more ingredients in the contrast agent or history of hypersensitivity to gadolinium or metals
• Sickle cell anemia
• Likely to undergo an invasive examination within 72 hours after administration of the investigational product